Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DMK DMK Pharmaceuticals (DMK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About DMK Pharmaceuticals Stock (NASDAQ:DMK) 30 days 90 days 365 days Advanced Chart Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get DMK Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.04▼$0.5852-Week Range N/AVolume24.16 million shsAverage Volume1.16 million shsMarket Capitalization$2.34 millionP/E RatioN/ADividend YieldN/APrice Target$1.50Consensus RatingBuy Company OverviewDMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.Read More… JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Receive DMK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DMK Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DMK Stock News HeadlinesAdamis Pharmaceuticals Corp (CY3.MU)September 21, 2024 | nz.finance.yahoo.com‘Forgets 26 other states & 8 UTs’: Abhishek Banerjee, Tharoor blast Modi govt’s Budget in Lok SabhaJuly 25, 2024 | msn.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 26, 2024 | WealthPress (Ad)DMK's Kanimozhi NVN Somu raises concerns over dubious breast cancer drug trials in India; to meet J P NaddaJuly 25, 2024 | msn.comTech analyst explains why he is long Apple stock into earningsMay 2, 2024 | uk.investing.comAustralia jobs shrink slightly in March, but labor market remains tightApril 19, 2024 | msn.comEarly Easter causes EU new car sales to drop 5.2% in March, says ACEAApril 19, 2024 | uk.investing.comIndia to become 3rd largest economy if PM Modi returns to power: JP NaddaApril 8, 2024 | msn.comSee More Headlines DMK Stock Analysis - Frequently Asked Questions What other stocks do shareholders of DMK Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that DMK Pharmaceuticals investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Sangamo Therapeutics (SGMO) and Bakkt (BKKT). Company Calendar Today11/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DMK CUSIPN/A CIK887247 Webwww.dmkpharmaceuticals.com Phone858-997-2400FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$1.50 High Stock Price Target$1.50 Low Stock Price Target$1.50 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,480,000.00 Net Margins-630.85% Pretax Margin-600.29% Return on EquityN/A Return on Assets-251.02% Debt Debt-to-Equity RatioN/A Current Ratio0.58 Quick Ratio0.54 Sales & Book Value Annual Sales$3.62 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.38) per share Price / BookN/AMiscellaneous Outstanding Shares10,102,000Free Float9,506,000Market Cap$2.34 million OptionableNo Data Beta1.11 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:DMK) was last updated on 11/26/2024 by MarketBeat.com Staff From Our PartnersJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredYour 401(k) vs. BRICS: The Battle for Your Financial FutureAs Global Powers Plot the Dollar's Demise Your Retirement Hangs by a Thread While the mainstream media stay...American Hartford Gold | Sponsored140% Yields From Stocks Like Tesla? Here's How (Black Friday Special)140% Dividends from stocks like Tesla? Discover How for Just $9! For Black Friday, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DMK Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DMK Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DMK Stock Alerts